Most Recent
A judge has granted most of the documents sought by a shareholder class action against Origin Energy but declined to make a ‘safety net’ discovery order, agreeing with the energy company that it was unnecessary.
The High Court has rejected former political staffer Bruce Lehrmann's special leave application seeking to appeal civil findings that he raped colleague Brittany Higgins.
A judge has rejected a bid by Toyota's finance arm to require group members in two class actions to register ahead of mediation to participate in any settlement arising from mediation in the cases.
A hearing set for this week on relief sought by Fortnite maker Epic Games in its competition case against Google will not go ahead as planned, after the companies reached a global settlement. But the terms of the deal remain to be approved by the ACCC.
Construction PRO
Lawyers assured two Dexus executives that it was OK to share the confidential information of Melbourne Airport operator APAC with proposed purchasers of the real estate asset manager's stake in the company, a court has heard.
Construction PRO
Liquidators for defunct construction group Hastie have launched a bid in its Federal Court case against Hall & Wilcox to refer a $18.6 million bill from the law firm to a costs assessor.
A judge has asked for more information on why he should approve $43.1 million in legal fees in a class action against AMP that settled for $120 million, calling the amount "extraordinary" and "troubling".
Construction PRO
A judge has threatened to vacate the trial in Dexus’ case against Melbourne Airport operator APAC after all the defendants tried to file documents late, suggesting the lawyers may be hit with personal costs orders.
A judge has said he will not be able to decide all the suppression applications in the ACCC’s misuse of market power case against Mastercard ahead of trial, saying the court was facing an “unreasonable, if not oppressive” burden.
Pharmacor is resisting AstraZeneca’s notice to produce in an intellectual property fight over diabetes drug Forxiga, claiming privilege over material evidencing its consideration of a new claim challenging the validity of a patent extension.